Skip to main content
  • More from ADA
    • Diabetes Care
    • Clinical Diabetes
    • Diabetes Spectrum
    • ADA Standards of Medical Care in Diabetes
    • ADA Scientific Sessions Abstracts
    • BMJ Open Diabetes Research & Care
  • Subscribe
  • Log in
  • My Cart
  • Follow ada on Twitter
  • RSS
  • Visit ada on Facebook
Diabetes

Advanced Search

Main menu

  • Home
  • Current
    • Current Issue
    • Online Ahead of Print
    • ADA Scientific Sessions Abstracts
  • Browse
    • By Topic
    • Issue Archive
    • Saved Searches
    • ADA Scientific Sessions Abstracts
    • Diabetes COVID-19 Article Collection
    • Diabetes Symposium 2020
  • Info
    • About the Journal
    • About the Editors
    • ADA Journal Policies
    • Instructions for Authors
    • Guidance for Reviewers
  • Reprints/Reuse
  • Advertising
  • Subscriptions
    • Individual Subscriptions
    • Institutional Subscriptions and Site Licenses
    • Access Institutional Usage Reports
    • Purchase Single Issues
  • Alerts
    • E­mail Alerts
    • RSS Feeds
  • Podcasts
    • Diabetes Core Update
    • Special Podcast Series: Therapeutic Inertia
    • Special Podcast Series: Influenza Podcasts
    • Special Podcast Series: SGLT2 Inhibitors
    • Special Podcast Series: COVID-19
  • Submit
    • Submit a Manuscript
    • Submit Cover Art
    • ADA Journal Policies
    • Instructions for Authors
    • ADA Peer Review
  • More from ADA
    • Diabetes Care
    • Clinical Diabetes
    • Diabetes Spectrum
    • ADA Standards of Medical Care in Diabetes
    • ADA Scientific Sessions Abstracts
    • BMJ Open Diabetes Research & Care

User menu

  • Subscribe
  • Log in
  • My Cart

Search

  • Advanced search
Diabetes
  • Home
  • Current
    • Current Issue
    • Online Ahead of Print
    • ADA Scientific Sessions Abstracts
  • Browse
    • By Topic
    • Issue Archive
    • Saved Searches
    • ADA Scientific Sessions Abstracts
    • Diabetes COVID-19 Article Collection
    • Diabetes Symposium 2020
  • Info
    • About the Journal
    • About the Editors
    • ADA Journal Policies
    • Instructions for Authors
    • Guidance for Reviewers
  • Reprints/Reuse
  • Advertising
  • Subscriptions
    • Individual Subscriptions
    • Institutional Subscriptions and Site Licenses
    • Access Institutional Usage Reports
    • Purchase Single Issues
  • Alerts
    • E­mail Alerts
    • RSS Feeds
  • Podcasts
    • Diabetes Core Update
    • Special Podcast Series: Therapeutic Inertia
    • Special Podcast Series: Influenza Podcasts
    • Special Podcast Series: SGLT2 Inhibitors
    • Special Podcast Series: COVID-19
  • Submit
    • Submit a Manuscript
    • Submit Cover Art
    • ADA Journal Policies
    • Instructions for Authors
    • ADA Peer Review
Pathophysiology

Decreased Expression of Heat Shock Protein 72 In Skeletal Muscle of Patients With Type 2 Diabetes Correlates With Insulin Resistance

  1. Istvan Kurucz1,
  2. Ágota Morva1,
  3. Allan Vaag2,
  4. Karl-Fredrik Eriksson3,
  5. Xudong Huang3,
  6. Leif Groop3 and
  7. Laszlo Koranyi14
  1. 1Department of Cellular Biology, BIOREX Research and Development, Veszprem, Hungary
  2. 2Steno Diabetes Center, Gentofte, Denmark
  3. 3Department of Endocrinology, University of Lund, Wallenberg Laboratory, Malmö, Sweden
  4. 4Balatonfüred Heart Center Foundation, Balatonfüred, Hungary
    Diabetes 2002 Apr; 51(4): 1102-1109. https://doi.org/10.2337/diabetes.51.4.1102
    PreviousNext
    • Article
    • Figures & Tables
    • Info & Metrics
    • PDF
    Loading

    Article Figures & Tables

    Figures

    • Tables
    • FIG. 1.
      • Download figure
      • Open in new tab
      • Download powerpoint
      FIG. 1.

      Quantitation of Hsp-72 mRNA in human muscle biopsies and heat-shocked NIH-3T3 cells, using competitive RT-PCR. A: Equal amounts of total RNA isolated from human muscles was added to titrated quantities (as indicated) of sRNA (competitor). RT-PCR of this sRNA yielded a product that was 80 nucleotides (nt) shorter (210 nt) than the amplification output generated from the native human Hsp-72 mRNA (290 nt, target), and that could therefore be distinguishable on the gel. B: The ratios of the amplification products from the competitor and target (C/T) were plotted against the number of copies of competitor added, and the plot was used to determine the equivalence point (indicated by arrows) between sRNA and target RNA. C: Kinetics of Hsp-72 expression after heat treatment of mammalian cells. NIH-3T3 cells were heat-treated at 43°C for 30 min and then incubated at 37°C. Total RNA was isolated at the indicated time points after heat treatment, and the amount of Hsp-72-specific message was determined with the competitive quantitative method. Results from two independent experiments (open or filled circles) are shown. Arrows indicate the beginning and the end of heat treatment. Basal Hsp-72 levels are shown by the two triangles. *106 copy/μg total RNA.

    • FIG. 2.
      • Download figure
      • Open in new tab
      • Download powerpoint
      FIG. 2.

      Hsp-72 mRNA concentration in muscle tissues of control and type 2 diabetic patients. Amount of Hsp-72 messenger RNA was determined in muscle biopsies of six nondiabetic (control) and six type 2 diabetic patients (T2DM) using the competitive RT-PCR as described in research design and methods. Individual data are expressed, using log10 scale, as copies of Hsp-72 mRNA in 1 μg total RNA. The difference between the two groups is statistically significant (Mann-Whitney U test, P = 0.039). *106 copy/ μg total RNA.

    • FIG. 3.
      • Download figure
      • Open in new tab
      • Download powerpoint
      FIG. 3.

      Hsp-72 mRNA levels in muscle biopsies of control subjects and identical monozygotic twins discordant for type 2 diabetes. The amount of Hsp-72 messenger RNA was determined using the competitive RT-PCR as described in research design and methods. A: Individual data are shown, using log10 scale, as copies of Hsp-72 mRNA in 1 μg total RNA. Statistical differences between the different groups were calculated with the nonparametric Mann-Whitney U test. B: Comparison of the expression of Hsp-72 mRNA between nondiabetic and diabetic individuals in twin-pairs. ○, twins with type 2 diabetes; ▴, twins with IGT; ▵, twins with NGT. Statistical differences (Wilcoxon-paired test) between nondiabetic and diabetic twins: P = 0.0431 for type 2 diabetes vs. NGT; P = 0.1755 (NS) for type 2 diabetes vs. IGT; P = 0.028for type 2 diabetes vs. NGT+IGT. *106 copy/μg total RNA. Tw, twin; T2DM, type 2 diabetes.

    • FIG. 4.
      • Download figure
      • Open in new tab
      • Download powerpoint
      FIG. 4.

      Correlation between muscle Hsp-72 mRNA expression and rates of glucose and lipid turnover, as determined in protocol 2 (n = 36). All of the values are expressed as milligrams per kilogram FFM per minute. ○, control subjects; ▵, nondiabetic twins; ⧫, twins with type 2 diabetes. A: Insulin-stimulated total glucose uptake (RdI): control subjects: R = 0.531, P = 0.078 NS; nondiabetic subjects: R = 0.581, P = 0.0053; twins: R = 0.519, P = 0.0128; twins with type 2 diabetes: R = 0.441, NS. B: Insulin-stimulated glucose oxidation (GoxI): controls: R = 0.364, NS; nondiabetic subjects: R = 0.253, NS; twins: R = 0.564, P = 0.0068; twins with type 2 diabetes: R = 0.594, P = 0.0487. C: Net glycogen synthesis during insulin infusion (GsI): controls: R = 0.322, NS; nondiabetic subjects: R = 0.322, NS; twins: R = 0.514, P = 0.0137; twins with type 2 diabetes: R = 0.487, NS. D: lipid oxidation during insulin infusion (LipoxI): control subjects: R = −0.634, P = 0.0355; nondiabetic subjects: R = −0.425, P = 0.0416; twins: R = −0.389, P = 0.0623 (NS); twins with type 2 diabetes: R = 0.643, P = 0.0329 for. *106 copy/μg total RNA.

    Tables

    • Figures
    • TABLE 1

      Clinical characteristics of study subjects

      ParametersProtocol 1
      Protocol 2
      Type 2 diabetic subjectsControl subjectsType 2 diabetic co-twinsNondiabetic co-twinsControl subjects
      n (F/M)6 (1/5)6 (0/6)12 (5/7)12 (5/7)12 (6/6)
      Age (years)51 ± 448 ± 964 ± 364 ± 361 ± 2
      BMI (kg/m2)25.1 ± 2.727.1 ± 4.230.1 ± 1.327.5 ± 1.326.0 ± 1.0
      Fasting plasma glucose (mmol/l)8.9 ± 0.8*5.7 ± 0.211.4 ± 1.1*6.0 ± 0.2‡5.4 ± 0.2
      Fasting plasma insulin (μU/ml)NDND12.7 ± 1.6*7.3 ± 2.26.9 ± 0.9
      2-h glucose (mmol/l)NDND19.5 ± 1.7*8.1 ± 1.6‡5.7 ± 0.3
      Glucose uptake (mg · kg FFM−1 · min−1)2.8 ± 1.2†6.8 ± 2.25.2 ± 0.7*8.5 ± 0.8‡11.3 ± 0.9
      Glucose storage (mg · kg FFM−1 · min−1)NDND2.8 ± 0.6*4.8 ± 0.6‡7.6 ± 0.9
      Glucose oxidation (mg · kg FFM−1 · min−1)NDND2.4 ± 0.2*3.7 ± 0.23.8 ± 0.2
      Lipid oxidation (mg · kg FFM−1 · min−1)NDND1.23 ± 0.13*0.76 ± 0.180.65 ± 0.07
      • Data are means ± SD. ND, not determined in the study.

      • *

        * P < 0.01 compared with control subjects

      • †

        † P < 0.02 compared with control subjects;

      • ‡

        ‡ P < 0.05 compared with control subjects

    • TABLE 2

      Correlation between skeletal muscle Hsp-72 mRNA and plasma fasting glucose or insulin levels, and 2-h glucose levels during oral glucose tolerance testing in different subgroups of patients from protocol 2

      ParametersControl subjects without family background of diabetesNondiabetic subjectsTwins (all)Diabetic subjects
      n12242412
      Fasting glucose−0.106 (NS)−0.397 (NS)−0.391 (NS)−0.455 (NS)
      Fasting insulin−0.091 (NS)−0.197 (NS)−0.129 (NS)−0.210 (NS)
      2-h glucose−0.744 (0.0236)*−0.716 (0.0006)*−0.327 (NS)−0.263 (NS)
      • Data are R (P).

      • *

        * Statistically significant correlations.

    PreviousNext
    Back to top

    In this Issue

    April 2002, 51(4)
    • Table of Contents
    • Index by Author
    Sign up to receive current issue alerts
    View Selected Citations (0)
    Print
    Download PDF
    Article Alerts
    Sign In to Email Alerts with your Email Address
    Email Article

    Thank you for your interest in spreading the word about Diabetes.

    NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

    Enter multiple addresses on separate lines or separate them with commas.
    Decreased Expression of Heat Shock Protein 72 In Skeletal Muscle of Patients With Type 2 Diabetes Correlates With Insulin Resistance
    (Your Name) has forwarded a page to you from Diabetes
    (Your Name) thought you would like to see this page from the Diabetes web site.
    CAPTCHA
    This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
    Citation Tools
    Decreased Expression of Heat Shock Protein 72 In Skeletal Muscle of Patients With Type 2 Diabetes Correlates With Insulin Resistance
    Istvan Kurucz, Ágota Morva, Allan Vaag, Karl-Fredrik Eriksson, Xudong Huang, Leif Groop, Laszlo Koranyi
    Diabetes Apr 2002, 51 (4) 1102-1109; DOI: 10.2337/diabetes.51.4.1102

    Citation Manager Formats

    • BibTeX
    • Bookends
    • EasyBib
    • EndNote (tagged)
    • EndNote 8 (xml)
    • Medlars
    • Mendeley
    • Papers
    • RefWorks Tagged
    • Ref Manager
    • RIS
    • Zotero
    Add to Selected Citations
    Share

    Decreased Expression of Heat Shock Protein 72 In Skeletal Muscle of Patients With Type 2 Diabetes Correlates With Insulin Resistance
    Istvan Kurucz, Ágota Morva, Allan Vaag, Karl-Fredrik Eriksson, Xudong Huang, Leif Groop, Laszlo Koranyi
    Diabetes Apr 2002, 51 (4) 1102-1109; DOI: 10.2337/diabetes.51.4.1102
    del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
    • Tweet Widget
    • Facebook Like
    • Google Plus One

    Jump to section

    • Article
      • Abstract
      • RESEARCH DESIGN AND METHODS
      • RESULTS
      • DISCUSSION
      • Acknowledgments
      • Footnotes
      • REFERENCES
    • Figures & Tables
    • Info & Metrics
    • PDF

    Related Articles

    Cited By...

    More in this TOC Section

    • Podocyte EGFR Inhibits Autophagy Through Upregulation of Rubicon in Type 2 Diabetic Nephropathy
    • A High-Fat Diet Attenuates AMPK α1 in Adipocytes to Induce Exosome Shedding and Nonalcoholic Fatty Liver Development In Vivo
    • Multinucleated Giant Cells in Adipose Tissue Are Specialized in Adipocyte Degradation
    Show more Pathophysiology

    Similar Articles

    Navigate

    • Current Issue
    • Online Ahead of Print
    • Scientific Sessions Abstracts
    • Collections
    • Archives
    • Submit
    • Subscribe
    • Email Alerts
    • RSS Feeds

    More Information

    • About the Journal
    • Instructions for Authors
    • Journal Policies
    • Reprints and Permissions
    • Advertising
    • Privacy Policy: ADA Journals
    • Copyright Notice/Public Access Policy
    • Contact Us

    Other ADA Resources

    • Diabetes Care
    • Clinical Diabetes
    • Diabetes Spectrum
    • Scientific Sessions Abstracts
    • Standards of Medical Care in Diabetes
    • BMJ Open - Diabetes Research & Care
    • Professional Books
    • Diabetes Forecast

     

    • DiabetesJournals.org
    • Diabetes Core Update
    • ADA's DiabetesPro
    • ADA Member Directory
    • Diabetes.org

    © 2021 by the American Diabetes Association. Diabetes Print ISSN: 0012-1797, Online ISSN: 1939-327X.